Innate immunity pathway

The innate immunity pathway is the primary, non-specific defense mechanism of the host, designed to recognize and respond to conserved motifs on pathogens or damaged host cells (NIH, 2023). This pathway involves a diverse array of pattern recognition receptors (PRRs), including Toll-like receptors (TLRs), RIG-I-like receptors (RLRs), and NOD-like receptors (NLRs), which trigger signaling cascades like the NF-κB and IRF pathways (PubMed, PMID: 31034466). Activation leads to the rapid production of pro-inflammatory cytokines, chemokines, and type I interferons to contain infections and prime the adaptive immune response (StatPearls, 2023). Dysregulation of these processes is a hallmark of various pathologies, including sepsis, rheumatoid arthritis, and various cancers where the pathway may be either suppressed or chronically overactive (Wikipedia, "Innate immune system"). In drug discovery, specific nodes within this pathway are targeted to either boost immunity (e.g., STING agonists in oncology) or dampen excessive inflammation (e.g., NLRP3 inhibitors). Because "Innate immunity pathway" refers to a complex network of multiple distinct proteins rather than a single molecular entity, it is generally classified as a biological process or pathway rather than a specific therapeutic target.

Other names

Innate immune systemNon-specific immune systemPattern recognition receptor signaling pathway

Modulation of pattern recognition receptors (PRRs) and downstream signaling cascades to regulate the production of cytokines and interferons.